2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
Key Takeaways
- Non-modifiable fracture risk factors include advanced age (the strongest independent predictor), female sex, Caucasian/Asian ethnicity, low BMI (< 19 kg/m²), personal history of adult fragility fracture, and parental history of hip fracture.
- Modifiable risk factors encompass tobacco smoking (accelerates hepatic estrogen metabolism and exerts direct osteoblast toxicity), heavy alcohol use (>= 3 units/day), sedentary lifestyle, and inadequate calcium/vitamin D intake.
- Secondary osteoporosis affects up to 30% of postmenopausal women and >50% of men, driven by endocrine disorders (hyperparathyroidism, Cushing's, hyperthyroidism), malabsorption (celiac disease, Roux-en-Y gastric bypass), and hematologic malignancies (multiple myeloma).
- Systemic glucocorticoid therapy (prednisone >= 5 mg/day for >= 3 months) is the most common cause of secondary drug-induced osteoporosis, triggering rapid trabecular bone loss and fracture risk at higher BMD T-scores.
- Other key bone-demineralizing medications include enzyme-inducing anticonvulsants (accelerating CYP3A4-mediated vitamin D clearance), aromatase inhibitors (inducing complete estrogen depletion), androgen deprivation therapy, and chronic proton pump inhibitors.
Last updated: September 2026
2.4 Risk Factors, Secondary Causes, and Bone-Compromising Medications
Quick Answer: Clinical fracture risk assessment integrates non-modifiable factors (advanced age, female sex, Caucasian/Asian descent, BMI < 19 kg/m², prior adult fragility fracture, and parental hip fracture) with modifiable risks (cigarette smoking, excessive alcohol $\ge 3$ units/day, sedentary lifestyle, and calcium/vitamin D deficits). Secondary osteoporosis occurs in up to 30% of postmenopausal women and >50% of men, driven by endocrine disorders (hyperparathyroidism, Cushing's, hyperthyroidism, hypogonadism), gastrointestinal malabsorption (celiac disease, bariatric bypass, IBD), and hematologic malignancies (multiple myeloma). Systemic glucocorticoids (prednisone $\ge 5$ mg/day for $\ge 3$ months) represent the leading drug-induced cause of bone loss, followed by enzyme-inducing anticonvulsants, aromatase inhibitors, androgen deprivation therapy, and chronic proton pump inhibitors.
Clinical Risk Factors: Non-Modifiable vs. Modifiable
Comprehensive fracture risk evaluation requires combining DXA bone mineral density with independent clinical risk factors that compromise bone quality or elevate fall propensity:
Non-Modifiable Risk Factors
- Advanced Age: The single most powerful independent predictor of fracture. Age-related fracture risk increases exponentially due to microarchitectural decay, cortical thinning, increased intracortical porosity, declining neuromuscular reflexes, and higher fall incidence.
- Female Sex: Women possess a lower peak bone mass, smaller bone geometry, and undergo accelerated bone loss following menopause due to estrogen withdrawal, sustaining roughly 70% of all fragility fractures.
- Race / Ethnicity: Caucasian and Asian populations exhibit the highest incidence of osteoporosis and fractures. Hispanic individuals show intermediate risk. African American individuals generally possess thicker cortices, greater trabecular volume, and higher peak BMD; however, post-fracture mortality is disproportionately high.
- Low Body Habitus / Slender Frame: Low body weight (< 127 lbs or 57.7 kg) or low body mass index (BMI < 19 $\text{kg/m}^2$). Slender individuals experience reduced mechanical skeletal loading (lower strain-mediated osteogenesis via Wolff's law) and possess less adipose tissue, limiting peripheral aromatase conversion of adrenal androgens into estrogens.
- Personal History of Adult Fragility Fracture: Having sustained a low-trauma fracture in adulthood doubles to quadruples future fracture risk. This imminent fracture risk is highest within the initial 12 to 24 months post-fracture.
- Parental History of Hip Fracture: Maternal or paternal hip fracture carries a strong hereditary predisposition independent of BMD, serving as a key input in the FRAX assessment tool.
Modifiable Risk Factors
- Cigarette Smoking: Exerts multifactorial adverse effects: nicotine is directly cytotoxic to osteoblasts; smoking induces hepatic CYP450 enzymes that accelerate estrogen metabolism; induces earlier natural menopause by 1 to 2 years; reduces intestinal calcium absorption; and associates with lower body weight.
- Excessive Alcohol Consumption: Intake of 3 or more units of alcohol daily (e.g., >2 standard drinks/day) directly blunts osteoblast proliferation and matrix synthesis, triggers hypercortisolemia, impairs hepatic 25-hydroxylation of vitamin D, causes malnutrition, and markedly elevates fall risk through intoxication and cerebellar ataxia.
- Physical Inactivity / Sedentary Lifestyle: Prolonged immobilization or lack of weight-bearing and resistance exercise eliminates skeletal strain. In the absence of mechanical strain, osteocytes increase sclerostin production, arresting osteoblast Wnt signaling and promoting osteoclastic resorption (disuse osteopenia).
- Inadequate Calcium and Vitamin D Intake: Dietary calcium below 1000–1200 mg/day or vitamin D intake below 800–1000 IU/day (serum $25(\text{OH})\text{D} < 20$–30 ng/mL) triggers persistent secondary hyperparathyroidism, which mobilizes skeletal calcium stores to defend serum levels. Excessive caffeine and high sodium intake exacerbate renal hypercalciuria.
Secondary Causes of Osteoporosis: Systemic Etiologies
Secondary osteoporosis accounts for bone loss in up to 30% of postmenopausal women and over 50% of men. Underlying disorders should be investigated whenever bone loss is severe or disproportionate to age:
| Organ System | Disease Condition | Pathophysiological Mechanism | Characteristic Skeletal / DXA Pattern |
|---|---|---|---|
| Endocrine | Primary Hyperparathyroidism | Autonomous PTH secretion drives high-turnover cortical resorption | Preferential cortical bone loss; prominent deficit at 33% radius |
| Endocrine | Cushing's Syndrome | Chronic cortisol excess suppresses osteoblasts & induces apoptosis | Marked trabecular loss (lumbar spine); rib and vertebral fractures |
| Endocrine | Hyperthyroidism | Excess T3/T4 accelerates bone turnover, shortening cycle length | Generalized high-turnover bone loss across spine and hips |
| Endocrine | Hypogonadism | Sex steroid deficiency removes inhibition of RANKL | Rapid high-turnover trabecular loss mirroring early menopause |
| Gastrointestinal | Celiac Disease | Autoimmune villous atrophy causes calcium & vitamin D malabsorption | Low BMD accompanied by elevated PTH and low 25(OH)D |
| Gastrointestinal | Bariatric Bypass (Roux-en-Y) | Duodenal bypass eliminates active transcellular calcium uptake | Rapid secondary hyperparathyroidism and hip bone loss |
| Gastrointestinal | Inflammatory Bowel Disease | Systemic cytokine release (TNF-α) plus steroid-induced bone loss | Combined cortical and trabecular demineralization |
| Hematologic | Multiple Myeloma | Malignant plasma cells produce MIP-1α & DKK1, driving osteolysis | Diffuse severe osteopenia, lytic bone lesions, normal ALP |
| Rheumatologic | Rheumatoid Arthritis | Systemic inflammatory cytokines stimulate osteoclastogenesis | Periarticular and axial bone loss; elevated fracture risk |
| Renal | Chronic Kidney Disease (CKD) | Calcitriol deficiency and phosphate retention drive hyperparathyroidism | Mixed renal osteodystrophy, vascular calcification, fracture risk |
Bone-Active Medications
Pharmacological agents represent a major category of secondary bone loss:
Glucocorticoids (The #1 Cause of Secondary Osteoporosis)
Systemic administration of oral prednisone $\ge 5$ mg/day (or equivalent) for 3 consecutive months or longer is the leading cause of drug-induced osteoporosis.
- Mechanisms: Directly inhibits osteoblast differentiation (suppressing Runx2) and collagen synthesis, while accelerating osteoblast and osteocyte apoptosis; inhibits active intestinal calcium absorption (antagonizing calcitriol) and promotes renal hypercalciuria; suppresses pituitary gonadotropins.
- Clinical Presentation: Fractures occur at higher BMD T-scores (e.g., -1.5 to -2.0) compared to primary osteoporosis. Bone loss is rapid, with up to 10% to 15% loss occurring within the first 3 to 6 months of therapy, predominantly depleting trabecular bone in the spine and ribs.
Other High-Yield Bone-Active Medications
- Anticonvulsants (CYP450 Enzyme Inducers): Phenytoin, carbamazepine, and phenobarbital induce hepatic CYP3A4, accelerating catabolism of 25(OH)D and $1,25(\text{OH})_2\text{D}$ into inactive metabolites (calcitroic acid), causing hypocalcemia, secondary hyperparathyroidism, osteomalacia, and bone loss.
- Aromatase Inhibitors (AIs): Anastrozole, letrozole, and exemestane inhibit peripheral aromatase conversion of androgens to estrogens, causing near-total estrogen depletion and rapid bone loss (2%–4% annually at spine and hip).
- Androgen Deprivation Therapy (ADT): GnRH agonists (leuprolide) and antagonists (degarelix) ablate testosterone and estrogen simultaneously in men with prostate cancer, triggering rapid demineralization.
- Proton Pump Inhibitors (PPIs): Chronic omeprazole or pantoprazole elevates gastric pH. Hypochlorhydria impairs dissolution of insoluble calcium carbonate; water-soluble calcium citrate is preferred.
- SSRIs, Heparin, and DMPA: SSRIs antagonize osteoblast serotonin receptors; prolonged unfractionated heparin stimulates resorption; and depot medroxyprogesterone (DMPA) suppresses gonadotropins, causing reversible bone loss.
| Medication Class | Common Agents | Primary Mechanism of Bone Loss | Management / Clinical Strategy |
|---|---|---|---|
| Glucocorticoids | Prednisone, dexamethasone | Osteoblast/osteocyte apoptosis, decreased Ca²⁺ absorption | Fracture risk elevated at higher T-scores; early bisphosphonate prophylaxis |
| Anticonvulsants | Phenytoin, carbamazepine | Induces CYP3A4; accelerates vitamin D catabolism | Monitor 25(OH)D levels; high-dose vitamin D and calcium repletion |
| Aromatase Inhibitors | Anastrozole, letrozole | Complete ablation of peripheral estrogen synthesis | Baseline DXA scan; antiresorptive therapy if T-score < -2.0 |
| Androgen Deprivation | Leuprolide, degarelix | Profound suppression of testosterone and secondary estradiol | Baseline DXA; lifestyle optimization and antiresorptive therapy |
| Proton Pump Inhibitors | Omeprazole, pantoprazole | Hypochlorhydria prevents ionization of calcium carbonate | Switch to calcium citrate; re-evaluate PPI indication |
| Depo-Provera (DMPA) | Medroxyprogesterone | Hypothalamic suppression reduces endogenous estradiol | Limit duration when possible; bone loss recovers upon cessation |
Test Your Knowledge
Which pharmacological agent is recognized as the leading cause of secondary (drug-induced) osteoporosis, producing accelerated trabecular bone loss and elevating fracture risk within the first 3 to 6 months of treatment?
A
B
C
D
Test Your Knowledge
How do enzyme-inducing antiepileptic medications, such as phenytoin, carbamazepine, and phenobarbital, contribute to skeletal demineralization and secondary osteoporosis?
A
B
C
D
Test Your Knowledge
A 56-year-old postmenopausal patient with hormone receptor-positive breast cancer is prescribed anastrozole, an aromatase inhibitor. By what biological mechanism does this medication accelerate bone loss and increase fracture risk?
A
B
C
D